In a development that could lead to a deeper understanding of cancer and better early-stage treatment of the disease, University of Michigan researchers have devised a reliable way to grow a certain type of cancer cells from patients outside the body for study.
Researchers at Swinburne University of Technology have discovered an instability in gold...
Univ. of California, Los Angeles researchers have developed a lens-free microscope that can be...
More than 90% of cancer-related deaths are caused by the spread of cancer cells from their...
A new study from Massachusetts Institute of Technology implicates a family of RNA-binding proteins in the regulation of cancer, particularly in a subtype of breast cancer. These proteins, known as Musashi proteins, can force cells into a state associated with increased proliferation.
Scientists often test drugs in mice. Now some cancer patients are doing the same—with the hope of curing their own disease. They are paying a private lab to breed mice that carry bits of their own tumors so treatments can be tried first on the customized rodents. The idea is to see which drugs might work best on a specific person's cancer.
One of the reasons cancer is so deadly is that it can evade attack from the body's immune system, which allows tumors to flourish and spread. Scientists can try to induce the immune system, known as immunotherapy, to go into attack mode to fight cancer and to build long lasting immune resistance to cancer cells. Now, researchers have developed a non–surgical injection of programmable biomaterial to do so.
New research from Rice Univ. and the Univ. of Texas MD Anderson Cancer Center shows how ovarian tumors co-opt a specific type of adult stem cell from abdominal tissues to fuel their growth. The research, published online in Cancer Research, suggests a new way to target aggressive ovarian cancers by disrupting the metabolic processes that allow them to thrive.
The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found. The trial included patients with melanoma or cancers of the lung, kidney, colon, GI tract, or head and neck, whose tumors were evaluated for PD-L1 expression by a novel assay.
Many older people silently harbor a blood "pre-cancer"—a gene mutation acquired during their lifetime that could start them on the path to leukemia, lymphoma or other blood disease, scientists have discovered. It opens a new frontier on early detection and possibly someday preventing these cancers, which become more common with age.
Conventional treatment seeks to eradicate cancer cells by drugs and therapy delivered from outside the cell, which may also affect (and potentially harm) nearby normal cells. In contrast to conventional cancer therapy, a Univ. of Cincinnati team has developed several novel designs for iron-oxide based nanoparticles that detect, diagnose and destroy cancer cells using photo-thermal therapy (PTT).
Scientists from Lawrence Berkeley National Laboratory have learned new details about how an important tumor-suppressing protein, called p53, binds to the human genome. As with many things in life, they found that context makes a big difference. The researchers mapped the places where p53 binds to the genome in a human cancer cell line.
Recent studies showing acid ceramidase (AC) to be upregulated in melanoma, lung and prostate cancers have made the enzyme a desired target for novel synthetic inhibitor compounds. In Angewandte Chemie, scientists with the Univ. of California, Irvine School of Medicine and the Italian Institute of Technology describe the very first class of AC inhibitors that may aid in the efficacy of chemotherapies.
A trawl through a library of more than 50,000 small molecules has identified a potential candidate to inhibit the spread of cancer cells throughout the body. Reported in Nature Communications, the molecule targets a mechanism of tumor development that had previously been considered “undruggable” and could open the door to further promising new candidates.
North Carolina State Univ. researchers have developed a potential new weapon in the fight against cancer: a daisy-shaped drug carrier that’s many thousands of times smaller than the period at the end of this sentence. Once injected into the bloodstream, millions of these “nanodaisies” sneak inside cancer cells and release a cocktail of drugs to destroy them from within.
A study conducted in part at the SLAC National Accelerator Laboratory has revealed how a key human protein switches from a form that protects cells to a form that kills them—a property that scientists hope to exploit as a “kill switch” for cancer. The protein, called cIAP1, shields cells from programmed cell death, or apoptosis.
Medicare may soon begin paying for yearly scans to detect lung cancer in certain current or former heavy smokers. The Centers for Medicare and Medicaid Services on Monday issued a long-awaited proposal to begin covering the screening for high-risk beneficiaries if their doctors agree they meet the criteria.
Every day, some of your cells stop dividing, and that’s a good thing. Cells that proliferate indefinitely are immortal, an essential early step in the development of most malignant tumors. Despite its importance in cancer, the process of cell immortalization is poorly understood. That’s because scientists have lacked a good way to study immortalization in human cells as it occurs during cancer progression.
A new technology that may assist in the treatment of brain cancer and other neurological diseases is the subject of an article in Technology. According to the authors, the current medical use of chemotherapy to treat brain cancer can be inefficient because of the blood-brain-barrier that impedes the delivery of drugs out of blood vessels and into the tumor.
A team led by Virginia Tech researchers studied cells found in breast and other types of connective tissue and discovered new information about cell transitions that take place during wound healing and cancer. They developed mathematical models to predict the dynamics of cell transitions, and by comparison gained new understanding of how a substance known as transforming growth factor triggers cell transformations.
Cancer researchers have found that a simple blood test might help diagnose pancreatic cancer, one of the most deadly forms of the disease. In new research at Indiana Univ., scientists have found that several microRNAs, which are small RNA molecules, circulate at high levels in the blood of pancreatic cancer patients.
Starting Monday, millions of people who have avoided colon cancer screening can get a new home test that's noninvasive and doesn't require the icky preparation most other methods do. The test is the first to look for cancer-related DNA in stool. But deciding whether to get it is a more complex choice than ads for "the breakthrough test ... that's as easy as going to the bathroom" make it seem.
A group of scientists in Florida have combined medicine and advanced nanotechnological engineering to create a smarter, more targeted therapy that could overcome the most lethal gynecologic cancer. The technology involves combining Taxol, a chemotherapy drug, with magneto-electric nanoparticles that can penetrate the blood-brain barrier.
Buoyed by several dramatic advances, Lawrence Livermore National Laboratory (LLNL) scientists think they can tackle biological science in a way that couldn't be done before. Over the past two years, LLNL researchers have expedited accelerator mass spectrometer sample preparation and analysis time from days to minutes and moved a complex scientific process requiring accelerator physicists into routine laboratory usage.
Nanomedicines consisting of nanoparticles for targeted drug delivery to specific tissues and cells offer new solutions for cancer diagnosis and therapy. Understanding the interdependency of physiochemical properties of nanomedicines, in correlation to their biological responses and functions, is crucial for their further development of as cancer-fighters.
Like discriminating thieves, prostate cancer tumors scavenge and hoard copper that is an essential element in the body. But such avarice may be a fatal weakness. Researchers at Duke Medicine have found a way to kill prostate cancer cells by delivering a trove of copper along with a drug that selectively destroys the diseased cells brimming with the mineral, leaving non-cancer cells healthy.
Biomedical engineering researchers have developed a drug delivery system consisting of nanoscale “cocoons” made of DNA that target cancer cells and trick the cells into absorbing the cocoon before unleashing anticancer drugs. The new system is DNA-based, which means it is biocompatible and less toxic to patients than systems that use synthetic materials.
New research involving scientists in the U.S. and Israel offers new insight into the lethal interaction between cancer cells and the immune system's communications network. The study authors devised a new computer program that models a specific channel of cell-to-cell communication involving exosomes that both cancer and immune cells harness to communicate with other cells. This “cyberwarfare” model reveals three distinct states of cancer.
It is estimated that as many as half of patients taking cancer drugs experience a decrease in mental sharpness, but what causes “chemo brain” has eluded scientists. In the study involving a sea snail that shares many of the same memory mechanisms as humans and a drug used to treat cancer, scientists in Texas identified memory mechanisms blocked by the drug. Then, they were able to counteract the mechanisms by administering another agent.
- Page 1